India’s pharma exports nearing $30 billion, with CRDMOs and GCCs driving next phase of innovation: EY-Parthenon–OPPI report 

• Report charts India’s next pharma growth curve — from the world’s pharmacy to a global innovation leader
• Highlights rise of CRDMOs, GCCs, and innovation-led growth as India shifts from scale to science

20 November 2025, Delhi: As India aspires to become a $30 trillion to $35 trillion economy by 2047, the pharmaceutical industry is poised to play a critical role in driving economic growth and enhancing public health, as per a latest report by EY Parthenon and Organisation of Pharmaceutical Producers of India (OPPI).  There are three interlinked pillars defining India's pharmaceutical industry: dominance in generics and vaccines, the advancing CRDMO/CDMO sector, and the expansion of Global Capability Centers.

Titled "Fueling innovation, advancing equity: The power of partnerships and digital-first strategies driving Indian pharma's global dominance”, the report highlights the transformative journey of India's pharmaceutical sector as it evolves from its historical role as the "pharmacy of the world" to a global leader in innovation and scientific research.

Primary insights from CXO interactions amongst pharma majors indicate that the industry must focus on long-term global leadership and importance of transitioning from a cost-driven model to one focused on innovation and value creation. They further highlighted the necessity for regulatory agility, increased R&D investment, and talent development as critical areas for fostering a robust pharmaceutical ecosystem.

Reflecting on the report launch, Suresh Subramanian, National Lifesciences Leader, EY Parthenon India said, “India’s pharma sector has been a stellar success story. While we have established ourselves as a global leader in generics and vaccines, we face challenges in transitioning to high-value innovation and advanced therapeutics. Key areas such as regulatory ease, investment in next-generation therapies, and the development of a skilled workforce require urgent attention. Our report shows a clear path forward, powered by strategic partnerships, digital acceleration, and policy enablers that can help India evolve from a manufacturing hub to a global life sciences innovation powerhouse.”

Adding to it, Mr. Anil Matai, Director General, Organisation of Pharmaceutical Producers of India said, “India's pharmaceutical industry stands at a pivotal moment, with the potential to redefine its global identity through innovation and collaboration. By focusing on high-value opportunities, enhancing regulatory frameworks, and fostering partnerships among stakeholders, India can solidify its position as a leader in pharmaceutical innovation and advanced manufacturing by 2047. The collective efforts of industry, government, and academia will be essential in realizing this vision, ensuring that India not only meets its ambitious economic goals but also contributes significantly to global health and well-being.

Key takeaways from the report:

1. Current Landscape: Strengths and Opportunities

The report highlights India's position as one of the fastest-growing large economies, with its GDP soaring from $2.1 trillion to $4.3 trillion over the past decade. The government aims to transform the country into a $30 trillion to $35 trillion economy by 2047, with the pharmaceutical sector as a cornerstone of this ambition. Currently, the industry ranks third globally in volume and fourteenth in value, accounting for approximately 20% of the global supply of generic drugs and 60% of global vaccines.

Additionally, the report reveals that pharmaceutical exports have surged from $15.07 billion in 2013-14 to $27.85 billion in FY 2023-24, with projections to exceed $30 billion soon. This growth is not only vital for economic advancement but also crucial for public health, as a healthier population enhances labor participation and mitigates the economic impact of diseases.

2. Rise of CRDMOs: Transforming the Landscape

The report emphasizes the emergence of Contract Research and Development Organizations (CRDMOs) and Contract Development and Manufacturing Organizations (CDMOs) as pivotal players in the pharmaceutical landscape. The global CRDMO market is projected to reach $303 billion by 2028, growing at a CAGR of 9.0%. This growth is driven by pharmaceutical companies increasingly outsourcing R&D and manufacturing to focus on core competencies.

Furthermore, the report finds that Indian CRDMOs are investing heavily in advanced manufacturing and analytics, positioning themselves as key partners in global research and development. This evolution allows India to transition from a low-cost production hub to an integrated partner in high-value innovation, enabling participation in cutting-edge science and technology.

3. Expansion of Global Capability Centers: Embedding Innovation

The establishment and expansion of Global Capability Centers (GCCs) by multinational pharmaceutical firms in India, is becoming critical to enhancing the country’s innovation ecosystem. Approximately 50% of leading global life sciences companies have set up GCCs in India, leveraging local talent and advanced digital capabilities.

These centers have evolved from mere cost-saving units to strategic assets that contribute significantly to enterprise-wide innovation and global business strategies. The report highlights that the integration of artificial intelligence, advanced analytics, and automation within GCCs is redefining drug discovery and development processes, positioning India as a global knowledge and innovation engine.

4. CXOs highlight critical gaps

The report captures a unanimous view from industry leaders, who express that the traditional generics model is becoming increasingly unsustainable due to price erosion and rising costs. They emphasise a pressing need to ‘upscale India's knowledge potential’ and build a ‘world-class R&D ecosystem.’ A key insight from these conversations is that ‘partnerships follow predictability,’ underscoring the critical need for strong intellectual property protection and regulatory clarity to attract the early-phase research that fuels true innovation.

A roadmap for global leadership

The report proposes a three-pronged strategy to unlock India’s $450 billion potential:

• Regulatory agility and policy leadership: Align Indian GMP standards with global benchmarks, participate actively in international forums, and create a CRDMO-specific regulatory pathway with Regulatory Data Protection (RDP) to enable early-phase trials and co-development.
• R&D investment and innovation financing: Drive high-risk research through public–private innovation funds for biologics, cell, and gene therapies. The report urges pharma companies to raise R&D spend beyond 10% of revenues and build co-innovation labs with academia and startups to bridge discovery and commercialization.
• Talent and capability development: Modernize academic curricula with AI/ML, bioinformatics, and regulatory science. Encourage collaboration between industry, CRDMOs, and GCCs to design job-ready programs, and link research grants to tangible outcomes such as IND filings.

About the survey:

The results outlined in the EY-OPPI report are informed by primary research completed in September-October 2025. Research included in-depth conversations and structured interviews with CXOs of prominent Indian and multinational pharmaceutical companies, Contract Research, Development and Manufacturing Organizations (CRDMOs), Global Capability Centers (GCCs), academic institutions, patient advocacy groups and other important healthcare stakeholder groups. This qualitative research was further supplemented by secondary research, industry data and analysis of global benchmarks presented to assess current strengths, growth levers and important gaps across the sector.

About EY-Parthenon:

With over 6,500 EY Parthenon professionals and 750+ partners across the globe, EY Parthenon is one of the largest strategy consultancies in the world. EY-P help CEOs and business leaders design and deliver transformative strategies across the entire enterprise, to help build long-term value to all stakeholders. With a result-oriented approach, EY-P teams bring experience and scale to each client, helping them to realize their strategies. By connecting teams and technologies from within EY-P and the broader EY ecosystem, EY-P can provide clients with corporate, transaction and turnaround strategies that are actionable and impactful and that help deliver long-term, sustainable value.

Whether it’s digital transformation, sector convergence and dislocation, or financial and operational complexities, EY-P teams bring data analytics, leading technology, and digital capabilities to a CEO’s toughest strategic issues. In doing so, EY Parthenon teams can move quickly from idea to implementation to help clients realize their strategy with speed and certainty; we call this Strategy Realized.

For more information about our organization, please visit https://www.ey.com/en_in/strategy/about-ey-parthenon

About OPPI:

The Organisation of Pharmaceutical Producers of India (OPPI) established in 1965, represents the research-based global pharmaceutical companies in India. OPPI has been an integral part of the healthcare journey of the country. We remain committed to supporting the nation’s healthcare objectives, putting patients at the core of all decision making and collaborating with all stakeholders to find sustainable solutions to realize the collective vision of Health for All.

Our member companies have been serving the country’s healthcare ecosystem since pre-independence and continue to remain committed to patient safety and providing quality care in the future as well. As an association, our advocacy decisions, patient commitment and work are always keeping the country first and we embody the spirit of working for ‘Bharat Ke Liye’; driven with innovation to find solutions for unmet medical needs, collaboration with Government stakeholders, and co-creation with partners coming together to address the nation’s healthcare challenges. We are committed to the Hon’ble Prime Minister Shri Narendra Modi-ji’s clarion call of ‘Jai Vigyan and Jai Anusandhan